SCHEMBL4097437

SCHEMBL4097437

O=C(Nc1ccc(Cl)c(Cl)c1)NC(c1ccc(C(=O)Nc2nn[nH]n2)cc1)c1ccc(C2=CCCCC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR2 O95136 1/20 0.40
S1PR4 O95977 1/20 0.40
S1PR1 P21453 1/20 0.40
S1PR3 Q99500 1/20 0.40
S1PR5 Q9H228 1/20 0.40
MGAT2 Q10469 2/20 0.39
LMNA P02545 3/20 0.39
MEN1 O00255 2/20 0.39
MAPT P10636 2/20 0.39
RAB9A P51151 2/20 0.39
KMT2A Q03164 2/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GCGR P47871 10/20 0.38
ADCY6 O43306 1/20 0.38
ADCY3 O60266 1/20 0.38
ADCY9 O60503 1/20 0.38
ADCY5 O95622 1/20 0.38
ADCY8 P40145 1/20 0.38
ADCY7 P51828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4091781 0.90 GCGR (0.43) MGAT2LMNAGCGRXDHCSF1R
SCHEMBL4086679 0.85 MGAT2 (0.42) MGAT2GCGRADCY6ADCY3ADCY9
SCHEMBL4087840 0.84 MGAT2 (0.45) MGAT2SMN1; SMN2GCGRADCY6ADCY3
SCHEMBL4096175 0.84 MGAT2 (0.40) MGAT2LMNAMEN1MAPTRAB9A
SCHEMBL4091306 0.84 MGAT2 (0.42) MGAT2LMNAMEN1KMT2AGCGR
SCHEMBL4085309 0.83 GCGR (0.51) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL4082123 0.83 GCGR (0.47) MGAT2GCGRGIPR
SCHEMBL4086859 0.82 GCGR (0.43) S1PR2S1PR4S1PR1S1PR3S1PR5
SCHEMBL4095204 0.82 GCGR (0.51) MGAT2LMNAGCGRADCY6ADCY3
SCHEMBL6192063 0.82 MGAT2 (0.46) MGAT2GCGRADCY6ADCY3ADCY9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR S1PR2 1740/4885S1PR4 1781/4885S1PR1 1399/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR S1PR2 1740/4885S1PR4 1781/4885S1PR1 1399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.